Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Income towards Parent Company: 2011-2024

Historic Income towards Parent Company for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $197.7 million.

  • Adma Biologics' Income towards Parent Company rose 1.45% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.4 million, marking a year-over-year increase of 207.41%. This contributed to the annual value of $197.7 million for FY2024, which is 800.00% up from last year.
  • Adma Biologics' Income towards Parent Company amounted to $197.7 million in FY2024, which was up 800.00% from -$28.2 million recorded in FY2023.
  • Adma Biologics' Income towards Parent Company's 5-year high stood at $197.7 million during FY2024, with a 5-year trough of -$76.6 million in FY2020.
  • Its 3-year average for Income towards Parent Company is $34.5 million, with a median of -$28.2 million in 2023.
  • Data for Adma Biologics' Income towards Parent Company shows a peak YoY soared of 800.00% (in 2024) over the last 5 years.
  • Adma Biologics' Income towards Parent Company (Yearly) stood at -$76.6 million in 2020, then grew by 6.81% to -$71.4 million in 2021, then climbed by 7.69% to -$65.9 million in 2022, then skyrocketed by 57.15% to -$28.2 million in 2023, then spiked by 800.00% to $197.7 million in 2024.